Fujii Yoshitaka, Tanaka Hiroyoshi, Somekawa Yoshiaki
Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan.
Department of Anesthesiology, Toride Kyodo General Hospital, Toride, Japan.
Curr Ther Res Clin Exp. 2004 Jul;65(4):321-9. doi: 10.1016/j.curtheres.2004.06.002.
Postoperative emetic symptoms (nausea, retching, and vomiting) frequently occur in women undergoing general anesthesia for abdominal hysterectomy. In a previous report by us, granisetron, a selective serotonin receptor antagonist, was more effective than the traditional antiemetics, droperidol and metoclopramide, for the treatment of postoperative emetic symptoms in this population.
The aim of this study was to determine the optimal dose of granisetron for the treatment of emetic symptoms following abdominal hysterectomy.
This randomized, double-blind, placebo-controlled, dose-ranging study was conducted at Toride Kyodo General Hospital (Toride, Japan). Female patients aged 33 to 66 years experiencing postoperative emetic symptoms after abdominal hysterectomy were eligible for the study. Patients received IV granisetron at 1 of 4 doses (10, 20, 40, or 100 μg/kg) or placebo; they were then observed for 24 hours. Emetic symptoms and the need for a rescue antiemetic were recorded by nursing staff, who were blinded to treatment assignment.
A total of 100 patients (mean [SD] age, 45 [7] years [range, 33-66 years]) were enrolled (n = 20 in each group). No significant differences in patient demographic characteristics were observed between the groups. The number of patients in whom complete control of postoperative emetic symptoms, defined as being free of emetic symptoms and not needing rescue antiemetic medication for 24 hours after study drug administration, was established was significantly greater in 3 of the granisetron groups than in the placebo group (6 patients [30%]): granisetron 10 μg/kg, 7 patients (35%; P= NS); granisetron 20 μg/kg, 17 patients (85%; P = 0.001); granisetron 40 μg/kg, 17 patients (85%; P = 0.001); and granisetron 100 μg/kg, 16 patients (80%; P = 0.002). No clinically significant adverse events attributable to the study drug were observed in any group.
In this study of patients who experienced emetic symptoms after undergoing general anesthesia for abdominal hysterectomy, granisetron at doses ≥20 μg/kg was effective in the treatment of established postoperative emetic symptoms.
接受腹部子宫切除术全身麻醉的女性术后常出现呕吐症状(恶心、干呕和呕吐)。在我们之前的一份报告中,选择性5-羟色胺受体拮抗剂格拉司琼在治疗该人群术后呕吐症状方面比传统止吐药氟哌利多和甲氧氯普胺更有效。
本研究旨在确定格拉司琼治疗腹部子宫切除术后呕吐症状的最佳剂量。
本随机、双盲、安慰剂对照、剂量范围研究在日本鸟取协同综合医院(鸟取)进行。年龄在33至66岁之间、腹部子宫切除术后出现术后呕吐症状的女性患者符合研究条件。患者接受4种剂量(10、20、40或100μg/kg)之一的静脉注射格拉司琼或安慰剂;然后对其进行24小时观察。护理人员记录呕吐症状以及使用急救止吐药的必要性,护理人员对治疗分配情况不知情。
共纳入100例患者(平均[标准差]年龄,45[7]岁[范围33 - 66岁])(每组20例)。各治疗组患者的人口统计学特征无显著差异。在给药后24小时内,定义为无呕吐症状且无需急救止吐药物的术后呕吐症状完全得到控制的患者数量,在3个格拉司琼组中显著多于安慰剂组(6例患者[30%]):格拉司琼10μg/kg组,7例患者(35%;P = 无显著性差异);格拉司琼20μg/kg组,17例患者(85%;P = 0.001);格拉司琼40μg/kg组,17例患者(85%;P = 0.001);格拉司琼100μg/kg组,16例患者(80%;P = 0.002)。任何组均未观察到与研究药物相关的具有临床意义的不良事件。
在本项针对接受腹部子宫切除术全身麻醉后出现呕吐症状患者的研究中,剂量≥20μg/kg的格拉司琼对已出现的术后呕吐症状有效。